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Abstract
Clomiphene citrate (CC), a synthetic estrogen, is an efficient superovulator used in
infertility treatment. However pregnancy rates resulting from CC treatment are
low. Research has suggested that this may be due to an aberrant effect on
implantation; CC binds to estrogen receptors (ER) and may affect estrogen
responsive gene expression and thus implantation. This study investigates the
effect of CC on ERα, 90kDa heat shock protein (Hsp90) and Hoxa10 expression in
the rat uterus. Hsp90 binds to ERα in the absence of ligand and is involved in
inducing a high affinity ligand binding conformation in the ER and in
transactivation of the ER. Hoxa10 has been shown to be essential for uterine
receptivity to implantation. CC (0.25mg) was given to ovariectomized rats, either
alone or prior to a hormonal regime known to induce uterine receptivity for
implantation. Expression of ERα, Hsp90 and Hoxa10 was determined by Western
blotting, fluorescence immunocytochemistry and reverse transcription polymerase
chain reaction. The single dose CC treated rats were compared to the controls as
well as to ovariectomized rats treated with 0.5µg 17β estradiol (E2). The CC treated
pseudopregnant rats (CCPPPE treated) were compared to 5½ day pregnant and
pseudopregnant rats without CC (PPPE treated), to determine CCs effect at
implantation. E2 upregulated ERα and Hsp90 expression in the rat uterus
compared to controls (p<0.05). The finding for ERα was unexpected as other
studies have shown that E2 decreases ERα levels a few hours after administration
in the uterus. The present study therefore suggests a biphasic effect of E2 on ERα
expression in the rat uterus. The effect of E2 on Hsp90 and ERα also proposes a
balance between the levels of these two proteins in the uterus, to keep ERα in its
optimal state and suggests that too high and too low a concentration of Hsp90 may
both be inhibitory to ERα functioning. No significant difference was found in
ERα and Hsp90 expression between the non-receptive (vehicle treated) and the
receptive (PPPE treated) rat uteri, suggesting that these two genes are not markers
for receptivity. However E2 is known to induce implantation of donor blastocysts
in progesterone (P4) primed uteri. Therefore it is still essential for ERα to be
present at implantation. It is of interest that CC downregulated ERα levels both in
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the absence of ovarian hormones and at implantation in the rat uterus. It is
therefore proposed that this antiestrogenic effect would render the uterus less
sensitive to the E2 required to induce implantation, thus accounting for low
pregnancy rates with CC use. Although CC did not alter the expression of Hsp90
in this study, the reduction in ERα levels in response to CC may also upset the
balance in the expression of these two genes, which may affect the transcriptional
activity of ERα, and further prevent implantation. No clear results were obtained for
Hoxa10 expression with the Western blots. However based on the ICC results, CC
did not appear to affect Hoxa10 expression. Since P4 and not E2 is known to have
the predominant effect on Hoxa10 expression, it is likely that E2 analogs, such as
CC, would also not affect Hoxa10 expression to a significant degree. Future work
will aim to separate the different uterine compartments and to determine the effects
of CC on the expression of other implantation specific genes in the uterus.
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LIST OF ABBREVIATIONS
α alpha
α=0.05 statistics tests performed at the 5% level of significance
β beta
-/- homozygous mutant
-RT minus reverse transcriptase control
A untreated ovariectomized control sample
A260 Absorbance at 260nm
A280 Absorbance at 280nm
ACE Associated Chemical Enterprises
AF activation function
ANOVA one-way analysis of variance
APS ammonium persulfate
B saline treated (vehicle control) sample
bp base pairs
BSA bovine serum albumin
C oil treated (vehicle control) sample
C1 initial concentration
C2 final concentration
CC clomiphene citrate
CCPPPE treatment regime: 0.25mg clomiphene citrate on 1st day followed by
5mg progesterone on the 2nd and 3rd days and then 5mg progesterone
and 0.5µg 17β estradiol on the 4th day
cDNA complementary deoxyribonucleic acid
conc concentration
COX cyclooxygenase
D 0.25mg CC treated sample (single treatment)
DAB diaminobenzidine
DBD DNA binding domain
DF degrees of freedom
DF NUM degrees of freedom of the numerator
DF DEN degrees of freedom of the denominator
dH2O distilled water (autoclaved)
xix
DNase deoxyribonuclease
dNTPs deoxynucleotide triphosphate mix
DTT dithiothreitol
E 0.5µg 17β estradiol treated sample
E2 17β estradiol
EDTA ethylenediamine tetraacetate
ELISA enzyme linked immunosorbant assay
EP3 and EP4 prostaglandin E2 receptor subtypes
ER estrogen receptor
ERα estrogen receptor alpha
ERβ estrogen receptor beta
ERE estrogen response element
F SOOO treated (vehicle control) sample
Fig. Figure
FITC fluoroscein isothiocyanate
FSH follicle stimulating hormone
G 5½ day pregnant sample
GE glandular epithelium
GIFT gamete intra-fallopian tube transfer
gl glands
GnRH gonadotropin-releasing hormone
GR glucocorticoid receptor
GST glutathione-S-transferase
H PPPE (pseudopregnant) sample
H&E Haematoxylin and Eosin stain
H12 helix 12 of the estrogen receptor structure
H2O2 hydrogen peroxide
HeLa uterine cervical adenocarcinoma
Hox homeobox
Hsps heat shock proteins
Hsp70 70kDa heat shock protein
Hsp90 90kDa heat shock protein
I CCPPPE (CC treated pseudopregnant) sample
xx
ICC immunocytochemistry
IGF insulin-like growth factor
ip intraperitoneal
IVF in vitro fertilization
kDa kilo Daltons
LBD ligand binding domain
LE luminal epithelium
lu lumen
M molar
MCF7 breast carcinoma cell line
µg microgram
mg milligram
ml millilitre
mRNA messenger ribonucleic acid
MW molecular weight marker
myo myometrium
n sample size (number of observations)
NegI negative control in which the primary antibody is omitted
NegII negative control in which the secondary antibody is omitted
ng nanogram
N.H Null Hypothesis
NTC no template control
O oil treatment
p<0.05 significantly different at the 5% level of significance
p>0.05 not significantly different at the 5% level of significance
P4 progesterone
PBS phosphate buffered saline
PCR polymerase chain reaction
PE progesterone and 17β estradiol treatment
PPPE treatment regime to induce pseudopregnancy: 5mg progesterone on 
1st 2 days followed by 5mg progesterone and 0.5µg 17β estradiol on
the 3rd day
PR progesterone receptor
xxi
Prob probability
RBC red blood cells
RNase ribonuclease
rpm revolutions per minute
rRNA ribosomal ribonucleic acid
RT-PCR reverse transcription polymerase chain reaction
S saline treatment
sc subcutaneous
SDS sodium dodecyl sulphate
SDS-PAGE sodium dodecyl sulphate polyacrylamide gel electrophoresis
SEM Standard Error of the Mean
SERM selective estrogen receptor modulator
SOOO treatment regime: saline on 1st day; oil on the following 3 days
Std Dev standard deviation
str stroma
TAE Tris acetate EDTA
TBE Tris borate EDTA
TBS Tris buffered saline pH8
TBS-Tween Tris buffered saline with 0.05% Tween-20®
TEMED tetramethylethylenediamine
TGF-β transforming growth factor beta
TM melting temperature
UV ultraviolet light
V1 initial volume
V2 final volume
VEGF vascular endothelial growth factor
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